PV Bulletin

Sponsor guidance: New safety module on the annual safety report

New safety module guidance impacts the Annual Safety Report submission process in the EU.

Primary source: EMA - What's new RSS

PV Impact Brief

Urgency: HighConfidence: high

What changed

Guidance issued for mandatory use of the New Safety Module for ASR submission starting from 28 September 2026, affecting how clinical trial sponsors report safety information.

Why it matters

The shift to the New Safety Module standardizes the reporting process for clinical trials in the EU and ensures compliance with updated regulatory requirements, impacting how sponsors manage safety data.

Action needed

Sponsors must prepare for training on the new module and transition to its use for ASR submissions while ensuring all trial authorizations align with the timeline.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Sep 3, 2026

Full briefing

Practical implication

Sponsors must prepare for training on the new module and transition to its use for ASR submissions while ensuring all trial authorizations align with the timeline.

The EMA has introduced a new safety module for the Annual Safety Report (ASR) as part of the Clinical Trial Information System (CTIS). The new module will be integrated into the CTIS Sponsor Workspace on 28 September 2026, requiring all new ASRs to be submitted through this module after the go-live date. A two-month transition period will allow both the old and new functionalities to be used in parallel.

What changed: Guidance issued for mandatory use of the New Safety Module for ASR submission starting from 28 September 2026, affecting how clinical trial sponsors report safety information.

Why it matters: The shift to the New Safety Module standardizes the reporting process for clinical trials in the EU and ensures compliance with updated regulatory requirements, impacting how sponsors manage safety data.

Practical implication: Sponsors must prepare for training on the new module and transition to its use for ASR submissions while ensuring all trial authorizations align with the timeline.

View original source

  • Source: EMA - What's new RSS
  • Published at source: 2026-09-03T00:00:00.000Z
  • Discovered by monitor: 2026-09-03T21:46:08.702Z

Published from the regulator source ingestion pipeline after PV impact triage.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward